THREE BOSTON SCIENTIFIC DRUG-ELUTING STENT TRIALS MEET ESC TREATMENT GUIDELINES

Boston Scientific Corporation today announced that three of its drug-eluting stent clinical trials have been recognized as meeting the treatment guidelines of the European Society of Cardiology (ESC), which met this week in Stockholm. Boston Scientific's TAXUS IV, V and VI trials were cited as examples of the type of definitive clinical evidence that physicians should use in making treatment decisions. Of the five trials cited in the guidelines, Boston Scientific was the only drug-eluting stent manufacturer with more than one trial highlighted.

Yahoo News (http://biz.yahoo.com/prnews/050908/neth016.html?.v=25)